Type B Aortic Dissection After the Use of Tadalafil

Charlotte M. Lameijer; Ignace F. J. Tielliu; Mels F. van Driel; Clark J. Zeebregts

doi:10.1016/j.athoracsur.2011.07.016

Type B Aortic Dissection After the Use of Tadalafil

Charlotte M. Lameijer, Ignace F. J. Tielliu, Mels F. van Driel, Clark J. Zeebregts^*

^*Corresponding author for this work

Man, Biomaterials and Microbes (MBM)

Research output: Contribution to journal › Editorial › Academic › peer-review

3 Citations (Scopus)

Abstract

A 63-year-old male patient with a type B aortic dissection after the use of tadalafil, a phosphodiesterase type 5 inhibitor, is presented. The possible role of a novel predisposing factor-sexual activity combined with tadalafil-is reviewed. This report and three other cases add a new dimension to the known predisposing factors such as chronic systemic hypertension, hereditary connective tissue diseases-and congenital aortic valve diseases. However, the precise role of phosphodiesterase type 5 inhibitors in the pathophysiology of aortic dissection remains unknown. (Ann Thorac Surg 2012;93:651-3) (C) 2012 by The Society of Thoracic Surgeons

Original language	English
Pages (from-to)	651-653
Number of pages	3
Journal	Annals of thoracic surgery
Volume	93
Issue number	2
DOIs	https://doi.org/10.1016/j.athoracsur.2011.07.016
Publication status	Published - Feb-2012

Keywords

SILDENAFIL
EXERCISE
PRESSURE

Access to Document

10.1016/j.athoracsur.2011.07.016

Cite this

@article{735360daa3e74d0780ecd53d48abe358,

title = "Type B Aortic Dissection After the Use of Tadalafil",

abstract = "A 63-year-old male patient with a type B aortic dissection after the use of tadalafil, a phosphodiesterase type 5 inhibitor, is presented. The possible role of a novel predisposing factor-sexual activity combined with tadalafil-is reviewed. This report and three other cases add a new dimension to the known predisposing factors such as chronic systemic hypertension, hereditary connective tissue diseases-and congenital aortic valve diseases. However, the precise role of phosphodiesterase type 5 inhibitors in the pathophysiology of aortic dissection remains unknown. (Ann Thorac Surg 2012;93:651-3) (C) 2012 by The Society of Thoracic Surgeons",

keywords = "SILDENAFIL, EXERCISE, PRESSURE",

author = "Lameijer, {Charlotte M.} and Tielliu, {Ignace F. J.} and {van Driel}, {Mels F.} and Zeebregts, {Clark J.}",

year = "2012",

month = feb,

doi = "10.1016/j.athoracsur.2011.07.016",

language = "English",

volume = "93",

pages = "651--653",

journal = "Annals of thoracic surgery",

issn = "0003-4975",

publisher = "ELSEVIER SCIENCE INC",

number = "2",

}

TY - JOUR

T1 - Type B Aortic Dissection After the Use of Tadalafil

AU - Lameijer, Charlotte M.

AU - Tielliu, Ignace F. J.

AU - van Driel, Mels F.

AU - Zeebregts, Clark J.

PY - 2012/2

Y1 - 2012/2

N2 - A 63-year-old male patient with a type B aortic dissection after the use of tadalafil, a phosphodiesterase type 5 inhibitor, is presented. The possible role of a novel predisposing factor-sexual activity combined with tadalafil-is reviewed. This report and three other cases add a new dimension to the known predisposing factors such as chronic systemic hypertension, hereditary connective tissue diseases-and congenital aortic valve diseases. However, the precise role of phosphodiesterase type 5 inhibitors in the pathophysiology of aortic dissection remains unknown. (Ann Thorac Surg 2012;93:651-3) (C) 2012 by The Society of Thoracic Surgeons

AB - A 63-year-old male patient with a type B aortic dissection after the use of tadalafil, a phosphodiesterase type 5 inhibitor, is presented. The possible role of a novel predisposing factor-sexual activity combined with tadalafil-is reviewed. This report and three other cases add a new dimension to the known predisposing factors such as chronic systemic hypertension, hereditary connective tissue diseases-and congenital aortic valve diseases. However, the precise role of phosphodiesterase type 5 inhibitors in the pathophysiology of aortic dissection remains unknown. (Ann Thorac Surg 2012;93:651-3) (C) 2012 by The Society of Thoracic Surgeons

KW - SILDENAFIL

KW - EXERCISE

KW - PRESSURE

U2 - 10.1016/j.athoracsur.2011.07.016

DO - 10.1016/j.athoracsur.2011.07.016

M3 - Editorial

VL - 93

SP - 651

EP - 653

JO - Annals of thoracic surgery

JF - Annals of thoracic surgery

SN - 0003-4975

IS - 2

ER -